Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside.

On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estimates imply upside of more than 127%.

Rama believes the shares offer strong upside potential from the current trading range. He anticipates that as competitors’ clinical data emerges, the stock price of Vera Therapeutics (NASDAQ:VERA) could rise toward a more appropriate risk-adjusted valuation.

Back on January 16, Cantor Fitzgerald also reiterated its Overweight rating on Vera Therapeutics (NASDAQ:VERA). Based on a $100 target price, the stock offers nearly 137% upside at the current level.

The firm highlighted that conditions appear favorable for atacicept’s possible approval to treat IgA-related kidney disorder. It also pointed towards the company’s solid foundation for a successful launch, indicating a strong opportunity for market entry once it has obtained regulatory approvals.

Vera Therapeutics (NASDAQ:VERA) is a late-stage clinical biotechnology company that addresses immunological conditions. The company develops and commercializes transformative treatments for serious diseases, including immunoglobulin A nephropathy. It is currently developing MAU868, which is a monoclonal antibody for BK viremia infections in transplant patients.

While we acknowledge the risk and potential of VERA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VERA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.